126 related articles for article (PubMed ID: 36261021)
1. Hypothalamic orexin prevents non-alcoholic steatohepatitis and hepatocellular carcinoma in obesity.
Tsuneki H; Maeda T; Takata S; Sugiyama M; Otsuka K; Ishizuka H; Onogi Y; Tokai E; Koshida C; Kon K; Takasaki I; Hamashima T; Sasahara M; Rudich A; Koya D; Sakurai T; Yanagisawa M; Yamanaka A; Wada T; Sasaoka T
Cell Rep; 2022 Oct; 41(3):111497. PubMed ID: 36261021
[TBL] [Abstract][Full Text] [Related]
2. A new preclinical model of western diet-induced progression of non-alcoholic steatohepatitis to hepatocellular carcinoma.
Green CD; Weigel C; Brown RDR; Bedossa P; Dozmorov M; Sanyal AJ; Spiegel S
FASEB J; 2022 Jul; 36(7):e22372. PubMed ID: 35639028
[TBL] [Abstract][Full Text] [Related]
3. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model.
Van Campenhout S; Tilleman L; Lefere S; Vandierendonck A; Raevens S; Verhelst X; Geerts A; Van Nieuwerburgh F; Van Vlierberghe H; Devisscher L
Metabolism; 2020 Jun; 107():154220. PubMed ID: 32243868
[TBL] [Abstract][Full Text] [Related]
4. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
Tucker RD; Ciofoaia V; Nadella S; Gay MD; Cao H; Huber M; Safronenka A; Shivapurkar N; Kallakury B; Kruger AJ; Kroemer AHK; Smith JP
Dig Dis Sci; 2020 Jan; 65(1):189-203. PubMed ID: 31297627
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic blockade of ER stress and inflammation prevents NASH and progression to HCC.
Boslem E; Reibe S; Carlessi R; Smeuninx B; Tegegne S; Egan CL; McLennan E; Terry LV; Nobis M; Mu A; Nowell C; Horadagoda N; Henstridge DC; Mellett NA; Timpson P; Jones M; Denisenko E; Forrest ARR; Tirnitz-Parker JEE; Meikle PJ; Rose-John S; Karin M; Febbraio MA
Sci Adv; 2023 Sep; 9(37):eadh0831. PubMed ID: 37703359
[TBL] [Abstract][Full Text] [Related]
6. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
Morikawa R; Nakamoto N; Amiya T; Chu PS; Koda Y; Teratani T; Suzuki T; Kurebayashi Y; Ueno A; Taniki N; Miyamoto K; Yamaguchi A; Shiba S; Katayama T; Yoshida K; Takada Y; Ishihara R; Ebinuma H; Sakamoto M; Kanai T
J Hepatol; 2021 Mar; 74(3):511-521. PubMed ID: 33038434
[TBL] [Abstract][Full Text] [Related]
7. Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by modulating HMGB1-NF-κB translocation.
Afrin R; Arumugam S; Rahman A; Wahed MI; Karuppagounder V; Harima M; Suzuki H; Miyashita S; Suzuki K; Yoneyama H; Ueno K; Watanabe K
Int Immunopharmacol; 2017 Mar; 44():174-182. PubMed ID: 28110063
[TBL] [Abstract][Full Text] [Related]
8. ASMase regulates autophagy and lysosomal membrane permeabilization and its inhibition prevents early stage non-alcoholic steatohepatitis.
Fucho R; Martínez L; Baulies A; Torres S; Tarrats N; Fernandez A; Ribas V; Astudillo AM; Balsinde J; Garcia-Rovés P; Elena M; Bergheim I; Lotersztajn S; Trautwein C; Appelqvist H; Paton AW; Paton JC; Czaja MJ; Kaplowitz N; Fernandez-Checa JC; García-Ruiz C
J Hepatol; 2014 Nov; 61(5):1126-34. PubMed ID: 24946279
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.
Ikawa-Yoshida A; Matsuo S; Kato A; Ohmori Y; Higashida A; Kaneko E; Matsumoto M
Int J Exp Pathol; 2017 Aug; 98(4):221-233. PubMed ID: 28895242
[TBL] [Abstract][Full Text] [Related]
10. Bicyclol alleviates high-fat diet-induced hepatic ER stress- and autophagy-associated non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in mice.
Jia S; Jin L; Cheng X; Wu J; Yao X; Shao J; Zhang C; Cen D; Cheng B; Wang J; Chen L; Yao X
Drug Dev Ind Pharm; 2022 Jun; 48(6):247-254. PubMed ID: 35875932
[TBL] [Abstract][Full Text] [Related]
11. C-type natriuretic peptide (CNP) in endothelial cells attenuates hepatic fibrosis and inflammation in non-alcoholic steatohepatitis.
Bae CR; Hino J; Hosoda H; Miyazato M; Kangawa K
Life Sci; 2018 Sep; 209():349-356. PubMed ID: 30114411
[TBL] [Abstract][Full Text] [Related]
12. Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC.
Grohmann M; Wiede F; Dodd GT; Gurzov EN; Ooi GJ; Butt T; Rasmiena AA; Kaur S; Gulati T; Goh PK; Treloar AE; Archer S; Brown WA; Muller M; Watt MJ; Ohara O; McLean CA; Tiganis T
Cell; 2018 Nov; 175(5):1289-1306.e20. PubMed ID: 30454647
[TBL] [Abstract][Full Text] [Related]
13. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.
Xu B; Jiang M; Chu Y; Wang W; Chen D; Li X; Zhang Z; Zhang D; Fan D; Nie Y; Shao F; Wu K; Liang J
J Hepatol; 2018 Apr; 68(4):773-782. PubMed ID: 29273476
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects.
Kawakubo M; Tanaka M; Ochi K; Watanabe A; Saka-Tanaka M; Kanamori Y; Yoshioka N; Yamashita S; Goto M; Itoh M; Shirakawa I; Kanai S; Suzuki H; Sawada M; Ito A; Ishigami M; Fujishiro M; Arima H; Ogawa Y; Suganami T
Sci Rep; 2020 Jan; 10(1):983. PubMed ID: 31969650
[TBL] [Abstract][Full Text] [Related]
15. Sodium alginate prevents progression of non-alcoholic steatohepatitis and liver carcinogenesis in obese and diabetic mice.
Miyazaki T; Shirakami Y; Kubota M; Ideta T; Kochi T; Sakai H; Tanaka T; Moriwaki H; Shimizu M
Oncotarget; 2016 Mar; 7(9):10448-58. PubMed ID: 26871288
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet.
Ganguly S; Muench GA; Shang L; Rosenthal SB; Rahman G; Wang R; Wang Y; Kwon HC; Diomino AM; Kisseleva T; Soorosh P; Hosseini M; Knight R; Schnabl B; Brenner DA; Dhar D
Cell Mol Gastroenterol Hepatol; 2021; 12(3):891-920. PubMed ID: 34062281
[TBL] [Abstract][Full Text] [Related]
17. Impact of osteopontin on the development of non-alcoholic liver disease and related hepatocellular carcinoma.
Nardo AD; Grün NG; Zeyda M; Dumanic M; Oberhuber G; Rivelles E; Helbich TH; Markgraf DF; Roden M; Claudel T; Trauner M; Stulnig TM
Liver Int; 2020 Jul; 40(7):1620-1633. PubMed ID: 32281248
[TBL] [Abstract][Full Text] [Related]
18. Addressing the liver progenitor cell response and hepatic oxidative stress in experimental non-alcoholic fatty liver disease/non-alcoholic steatohepatitis using amniotic epithelial cells.
Goonetilleke M; Kuk N; Correia J; Hodge A; Moore G; Gantier MP; Yeoh G; Sievert W; Lim R
Stem Cell Res Ther; 2021 Jul; 12(1):429. PubMed ID: 34321089
[TBL] [Abstract][Full Text] [Related]
19. L-carnitine prevents progression of non-alcoholic steatohepatitis in a mouse model with upregulation of mitochondrial pathway.
Ishikawa H; Takaki A; Tsuzaki R; Yasunaka T; Koike K; Shimomura Y; Seki H; Matsushita H; Miyake Y; Ikeda F; Shiraha H; Nouso K; Yamamoto K
PLoS One; 2014; 9(7):e100627. PubMed ID: 24983359
[TBL] [Abstract][Full Text] [Related]
20. Elevation of liver endoplasmic reticulum stress in a modified choline-deficient l-amino acid-defined diet-fed non-alcoholic steatohepatitis mouse model.
Muraki Y; Makita Y; Yamasaki M; Amano Y; Matsuo T
Biochem Biophys Res Commun; 2017 May; 486(3):632-638. PubMed ID: 28322783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
